68 related articles for article (PubMed ID: 38411963)
21. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
22. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract][Full Text] [Related]
23. Clinical Significance of the Stromatic Component in Ovarian Cancer: Quantity Over Quality in Outcome Prediction.
Lou E; Clemente V; Grube M; Svedbom A; Nelson A; Blome F; Staebler A; Kommoss S; Bazzaro M
bioRxiv; 2023 Jun; ():. PubMed ID: 37425832
[TBL] [Abstract][Full Text] [Related]
24. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
26. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
27. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
[TBL] [Abstract][Full Text] [Related]
28. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
Zhang Q; Ding J; Wang Y; He L; Xue F
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35362546
[TBL] [Abstract][Full Text] [Related]
30. The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types.
Micke P; Strell C; Mattsson J; Martín-Bernabé A; Brunnström H; Huvila J; Sund M; Wärnberg F; Ponten F; Glimelius B; Hrynchyk I; Mauchanski S; Khelashvili S; Garcia-Vicién G; Molleví DG; Edqvist PH; O Reilly A; Corvigno S; Dahlstrand H; Botling J; Segersten U; Krzyzanowska A; Bjartell A; Elebro J; Heby M; Lundgren S; Hedner C; Borg D; Brändstedt J; Sartor H; Malmström PU; Johansson M; Nodin B; Backman M; Lindskog C; Jirström K; Mezheyeuski A
EBioMedicine; 2021 Mar; 65():103269. PubMed ID: 33706249
[TBL] [Abstract][Full Text] [Related]
31.
Lou E
Front Oncol; 2020; 10():559548. PubMed ID: 33324545
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
Lou E; Vogel RI; Hoostal S; Wong P; Grad A; Monu M; Łukaszewski T; Deshpande J; Dickson EL; Klein M; Linden MA; Subramanian S; Teoh D; Geller MA
Oncologist; 2019 Nov; 24(11):1422-e1013. PubMed ID: 31346130
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer.
Lou E; Vogel RI; Hoostal S; Klein M; Linden MA; Teoh D; Geller MA
JAMA Oncol; 2019 Aug; 5(8):1222-1224. PubMed ID: 31152668
[TBL] [Abstract][Full Text] [Related]
34. Cellular and Molecular Networking Within the Ecosystem of Cancer Cell Communication via Tunneling Nanotubes.
Lou E; Zhai E; Sarkari A; Desir S; Wong P; Iizuka Y; Yang J; Subramanian S; McCarthy J; Bazzaro M; Steer CJ
Front Cell Dev Biol; 2018; 6():95. PubMed ID: 30333973
[TBL] [Abstract][Full Text] [Related]
35. Tumor evolution and chemoresistance in ovarian cancer.
Kim S; Han Y; Kim SI; Kim HS; Kim SJ; Song YS
NPJ Precis Oncol; 2018; 2():20. PubMed ID: 30246154
[TBL] [Abstract][Full Text] [Related]
36. Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
Drakes ML; Stiff PJ
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200478
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer.
Desir S; O'Hare P; Vogel RI; Sperduto W; Sarkari A; Dickson EL; Wong P; Nelson AC; Fong Y; Steer CJ; Subramanian S; Lou E
Sci Rep; 2018 Jun; 8(1):9484. PubMed ID: 29930346
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
